# A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct06308406/  
OnCo record `nct06308406` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is unknown.

## Summary

The registry lists NCT06308406 as unknown, last updated 2024-04-11. Enrolment is 54 planned participants, an estimate. Interventions: Bevacizumab； HRS-1167. Primary measures include The number of subjects with dose-limiting toxicity (DLT); Determination of Recommended Phase II dose (RP2D). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Last checked: 2026-10-06
- Registry id: NCT06308406
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.

## Sources

- ClinicalTrials.gov NCT06308406: https://clinicaltrials.gov/study/NCT06308406

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/)

---
JSON: https://onco.cc/api/v1/entities/nct06308406.json